• Jill C. Milne, Ph.D.

    Co-Founder and Chief Executive officer
      Jill C. Milne, Ph.D., is a co-founder of our company and has served as a member of our board of directors and as our President and Chief Executive Officer since June 2008. Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr. Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr. Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley College.
      • Noah Clauser, CPA

        Chief Financial Officer
        Noah Clauser, CPA
          Noah Clauser has served as Chief Financial Officer since September 2020. Previously, he was the Vice President, Finance leading the finance and operations functions since August 2017. He served as Senior Director, Finance and Controller at Catabasis from January 2016 to July 2017 and as Controller from April 2011 to December 2015. Prior to joining Catabasis, Mr. Clauser was at Impress Software, an enterprise software company, where he served as Accounting Manager from 2005 to 2009. Mr. Clauser is a licensed CPA in Massachusetts and holds an M.S. in Accounting and a B.S. in Management from the University of Massachusetts at Boston.
          • Joanne Donovan, M.D., Ph.D.

            Chief Medical Officer and Senior Vice President, Clinical Development
            Joanne Donovan, M.D., Ph.D.
              Joanne M. Donovan, M.D., Ph.D., has served as our Chief Medical Officer since July 2011. Since 1989, she has worked as a staff physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr. Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate clinical professor of medicine. From 1998 to July 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a biotechnology company, which she joined through its acquisition of GelTex. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women's Hospital.
              • Andrew A. Komjathy

                Chief Commercial Officer
                Andrew A. Komjathy
                  Andrew A. Komjathy has served as our Chief Commercial Officer since September 2019. Prior to joining Catabasis, Mr. Komjathy was Vice President, Commercial Sales at Alkermes Inc. from May 2014 to November 2018. Previously, he was the Vice President, Sales for the U.S. Multiple Sclerosis Business Unit at Genzyme from 2012 to 2014. From 2005 to 2012, Mr. Komjathy held three Vice President positions at Shire Human Genetic Therapies, initially as Vice President and General Manager, Commercial Operations in the North American and Asia-Pacific regions, followed by Vice President, Global Franchise Leader for Fabry/Gaucher in Switzerland, and ultimately as Vice President, Commercial Operations. From 1996 to 2005, Mr. Komjathy held positions of increasing responsibility at Biogen. Mr. Komjathy holds an MBA from New York University Stern School of Business and his BS in Business Administration from Bucknell University. 
                  • Andrew Nichols, Ph.D.

                    Chief Scientific Officer
                    Andrew Nichols, Ph.D.
                      Andrew Nichols, Ph.D., has served as our Chief Scientific Officer since October 2016. Previously, he served as our Senior Vice President, Research and Development from February 2014 to October 2016. From October, 2013 to February, 2014, Dr. Nichols was Associate Vice President, Cardiometabolic Diseases at Merck Research Labs, a pharmaceutical research company, leading drug discovery and early clinical development programs. Dr. Nichols was also Associate Vice President/Executive Director, In Vivo Pharmacology at Merck Research Labs from August, 2010 to October, 2013, and Executive Director, In Vivo Sciences at Merck Research Labs from August, 2009 to August, 2010. Prior to Merck, Dr. Nichols was Vice President of Preclinical Research at Zafgen, Vice President of Research at Alinea, Vice President of Drug Discovery Project Leadership at Millennium and Director of the Alliance Management Group at SmithKline Beecham. He holds an M. Phil. and Ph.D. in Cardiovascular Pharmacology from the University of Cambridge, England and a B.Sc. in Pharmacology from the University of Leeds, England.
                      • Ben Harshbarger, J.D.

                        Senior Vice President, General Counsel
                          Ben Harshbarger joined Catabasis in June 2020 as our Senior Vice President, General Counsel. Prior to joining Catabasis, Mr. Harshbarger served as Interim Chief Executive Officer and General Counsel at Novelion Therapeutics Inc. from November 2018 to December 2019. He was General Counsel of Aegerion Pharmaceuticals, Inc. and subsequently Novelion Therapeutics following their merger from August 2016 to November 2018, and Acting General Counsel of Aegerion Pharmaceuticals from September 2015 to July 2016. Prior to these roles, he served as the  Vice President, EMEA Legal Counsel and the Vice President, Deputy General Counsel at Aegerion from 2012 to 2015. Mr. Harshbarger was also Senior Director, Associate General Counsel at Cubist Pharmaceuticals, Inc. from 2008 to 2012, Senior Director, Deputy General Counsel at Viacell, Inc. from 2006 to 2008, and Director/Senior Director, Associate General Counsel at Biogen from 2001 to 2006. Mr. Harshbarger received his J.D. from Boston College Law School, and his B.A. in Political Science from the University of Richmond.
                          • Andrea Matthews

                            Senior Vice President, Corporate Affairs
                            Andrea Matthews
                              Andrea Matthews has served as Senior Vice President, Corporate Affairs since October 2020, leading the investor relations, corporate communications, patient advocacy, corporate strategy, and business development functions. Previously, she served as Vice President, Corporate Affairs since August 2017, as Executive Director, Corporate Affairs since November 2015, and as Senior Director, Operations and Corporate Development from July 2014 to October 2015. Prior to joining Catabasis, Ms. Matthews served as Vice President, Operations and Alliance Management/Commercial Operations at Selventa (formerly Genstruct), a biomarker discovery company that collaborated with pharmaceutical and consumer product companies, from February 2010 to July 2014 and as Director, Alliance Management from February 2009 to February 2010. From 2003 to 2009, Ms. Matthews held a series of roles with increasing responsibilities at Genstruct, leading to several managerial positions. Ms. Matthews holds an MBA from the Massachusetts Institute of Technology Sloan School of Management and a B.A. in Biochemistry and Molecular Biology from Boston University.